Comparison of effectiveness of two different antibiotics courses in prevention of unfavourable health results of mother and baby in case of early rupture of membranes
Phase 4
- Conditions
- Health Condition 1: O429- Premature rupture of membranes, unspecified as to length of time between rupture and onset of labor
- Registration Number
- CTRI/2024/04/065733
- Lead Sponsor
- DrJyoti
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
– Patient giving written informed consent
– Singleton pregnancy, PPROM after 24 weeks of gestation & before 37 weeks.
Exclusion Criteria
-Not giving consent
– Conditions requiring expedite delivery or contraindication of conservative management like: Chorioamnionitis
Fetal distress
Placental abruption
Active labour
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method atency period <br/ ><br>Early neonatal sepsis rate-positive blood culture <br/ ><br>Chorioamnionitis rate <br/ ><br>Timepoint: Latency period-date of randomisation until date of delivery <br/ ><br>Early neonatal sepsis rate- within 3 days of delivery <br/ ><br>Chorioamnionitis rate-from day of randomisation until date of clinical/laboratory Chorioamnionitis diagnosis assessed up to 10 weeks <br/ ><br>
- Secondary Outcome Measures
Name Time Method eonatal weight <br/ ><br>Apgar score <br/ ><br> Neonatal intensive care unit (NICU) admission durationTimepoint: Neonatal weight [ Time Frame: at delivery] grams <br/ ><br> Apgar score [ Time Frame: 1 minute - 5minutes] score from 0 to 10 Other Neonatal intensive care unit (NICU) admission duration [Time Frame: days since delivery until rerelease from NICU, assessed up to 6 months]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie antibiotic efficacy in PPROM cases with O429 classification?
How do prophylactic antibiotic regimens in CTRI/2024/04/065733 compare to standard-of-care treatments for PPROM?
Which biomarkers are associated with favorable maternal and neonatal outcomes following PPROM antibiotic therapy?
What are the potential adverse events linked to prolonged antibiotic use in PPROM and how can they be managed?
Are there any combination therapies or alternative drugs showing promise in preventing PPROM complications compared to the regimens in CTRI/2024/04/065733?